LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Akcijų sąrašas・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.31 -8.82

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.31

Max

0.32

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-15M -35M
Pardavimai	-18M 581K
Pelno marža	-6,012.048
Darbuotojai	183
EBITDA	-15M -33M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+1775% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-30

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-50M 125M
Ankstesnė atidarymo kaina	9.13
Ankstesnė uždarymo kaina	0.31

Naujienos nuotaikos

By Acuity

67%

33%

303 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

0.5207 / 0.7223 Palaikymas ir pasipriešinimas

Sangamo Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-27 17:33; UTC

Svarbiausios naujienos

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026-03-27 17:00; UTC

Svarbiausios naujienos

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026-03-27 16:03; UTC

Svarbiausios naujienos

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026-03-29 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls Amid Rising Inflation Fears -- Market Talk

2026-03-29 23:46; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

2026-03-29 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

2026-03-29 23:23; UTC

Rinkos pokalbiai

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

2026-03-29 22:34; UTC

Rinkos pokalbiai

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

2026-03-29 22:09; UTC

Rinkos pokalbiai

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

2026-03-29 21:06; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

2026-03-29 21:03; UTC

Rinkos pokalbiai

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

2026-03-29 21:01; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

2026-03-29 09:30; UTC

Įsigijimai, susijungimai, perėmimai

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

2026-03-28 08:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 19:16; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026-03-27 19:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026-03-27 19:04; UTC

Rinkos pokalbiai

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026-03-27 19:03; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 19:02; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026-03-27 18:12; UTC

Rinkos pokalbiai

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026-03-27 17:36; UTC

Svarbiausios naujienos

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026-03-27 17:34; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026-03-27 17:29; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026-03-27 16:38; UTC

Rinkos pokalbiai

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026-03-27 16:32; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026-03-27 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-27 15:43; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-27 15:25; UTC

Rinkos pokalbiai

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sangamo Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

1775% į viršų

12 mėnesių prognozė

Vidutinis 6 USD 1775%

Aukščiausias 10 USD

Žemiausias 2 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sangamo Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Sangamo Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.5207 / 0.7223Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

303 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.